Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00419081 · ClinicalTrials.gov registry record · Phase 2
Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens
A Phase 2 study, sponsored by BioCryst Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00419081: Clinical Trial Phase 2 study, sponsored by BioCryst Pharmaceuticals.
NCT00419081 is a Phase 2 study that was terminated before completion, run by BioCryst Pharmaceuticals. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00419081, a Phase 2 study, was terminated before completion, sponsored by BioCryst Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Forodesine Hydrochloride is effective in treating patients with relapsed/refractory precursor T-Lymphoblastic Leukemia/Lymphoma who have failed two or more prior treatment regimens.
Interventions
- DRUG Forodesine Hydrochloride Sterile Solution, 5 mg/mL
- DRUG Forodesine Hydrochloride Capsules (100 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Why NCT00419081 stopped before completion
NCT00419081 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 2 interventions - of which Forodesine Hydrochloride Sterile Solution, 5 mg/mL is the first listed.
NCT00419081 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00419081 about?
NCT00419081 is a clinical study titled "Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens". The purpose of this study is to determine whether Forodesine Hydrochloride is effective in treating patients with relapsed/refractory precursor T-Lymphoblastic Leukemia/Lymphoma who have failed two or more prior treatment regimens.
What is the current status of trial NCT00419081?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2006-07. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00419081?
The interventions under investigation include: Forodesine Hydrochloride Sterile Solution, 5 mg/mL (DRUG), Forodesine Hydrochloride Capsules (100 mg) (DRUG).
Who is sponsoring clinical trial NCT00419081?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00419081's enrollment target sits among peer trials
100 672nd of 2000 higher than 1,263 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia